Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Agios Pharma (AGIO)
NASDAQ:AGIO
Holding AGIO?
Track your performance easily
AGIO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$22.23 - $62.58
Previous CloseN/A
Volume212.48K
Average Volume (3M)1.05M
Market Cap
$1.97B
Enterprise Value$1.65B
Total Cash (Recent Filing)$541.31M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)3.0
Beta1.95
Next Earnings
Feb 13, 2025EPS Estimate
-1.69Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)11.37
Shares Outstanding57,030,193
10 Day Avg. Volume742,764
30 Day Avg. Volume1,050,394
Standard Deviation0.14
R-Squared0.10
Alpha-0.00570
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)59.79
Price to Cash Flow (P/CF)-5.80
P/FCF Ratio0.00
Enterprise Value/Market Cap0.84
Enterprise Value/Revenue50.26
Enterprise Value/Gross Profit69.01
Enterprise Value/Ebitda-4.40
Forecast
1Y Price Target
$62.33Price Target Upside81.24% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Agios Pharma News
PremiumCompany Announcements
Agios Pharma Sets Milestones for Rare Disease Growth
Bulls Say, Bears Say
Bulls Say
Clinical TrialsAgios has reported positive data across all forms of thalassemia including demonstration of hemoglobin (Hb) increases, reduction in transfusions, and improvements in fatigue.
Market PotentialMitapivat has multi-billion dollar sales potential across thalassemia and sickle cell disease.
Regulatory AffairsThe FDA accepted the sNDA for Pyrukynd in adult patients with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia.
Bears Say
Clinical Trial ConcernsPrior data from the healthy volunteer trial included cases of treatment-related thrombocytopenia, which remains a concern for the higher doses being tested in the Phase 2b trial.
Commercial CompetitionShare weakness is likely also driven by PKR activator competitor readout from Novo Nordisk, which demonstrated comparable performance in VOC reduction and hemoglobin response.
Drug Safety ConcernsThe liver tox risk disclosed could impact the perception of the drug's safety.
---
Ownership Overview
1.50% Insiders
26.28% Mutual Funds
0.08% Other Institutional Investors
54.05% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AGIO FAQ
What was Agios Pharma’s price range in the past 12 months?
Agios Pharma lowest stock price was $22.23 and its highest was $62.58 in the past 12 months.
What is Agios Pharma’s market cap?
Agios Pharma’s market cap is $1.97B.
When is Agios Pharma’s upcoming earnings report date?
Agios Pharma’s upcoming earnings report date is Feb 13, 2025 which is in 11 days.
How were Agios Pharma’s earnings last quarter?
Agios Pharma released its earnings results on Oct 31, 2024. The company reported $16.22 earnings per share for the quarter, beating the consensus estimate of $15.216 by $1.004.
Is Agios Pharma overvalued?
According to Wall Street analysts Agios Pharma’s price is currently Undervalued.
Does Agios Pharma pay dividends?
Agios Pharma does not currently pay dividends.
What is Agios Pharma’s EPS estimate?
Agios Pharma’s EPS estimate is -1.69.
How many shares outstanding does Agios Pharma have?
Agios Pharma has 57,030,193 shares outstanding.
What happened to Agios Pharma’s price movement after its last earnings report?
Agios Pharma reported an EPS of $16.22 in its last earnings report, beating expectations of $15.216. Following the earnings report the stock price went down -4.039%.
Which hedge fund is a major shareholder of Agios Pharma?
Among the largest hedge funds holding Agios Pharma’s share is Farallon Capital Management, L.L.C.. It holds Agios Pharma’s shares valued at 252M.
---
Agios Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$62.33 (81.24% Upside)
$62.33 (81.24% Upside)
Blogger Sentiment
Bullish
AGIO Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 49.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 1.8%
Last 30 Days ▲ 1.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
60.20%
12-Months-Change
Fundamentals
Return on Equity
53.65%
Trailing 12-Months
Asset Growth
77.89%
Trailing 12-Months
Company Description
Agios Pharma
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.
---
AGIO Company Deck
---
AGIO Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a positive outlook with significant milestone achievements, strong financial positioning, and promising advancements in clinical trials. However, challenges remain, particularly in pediatric PK deficiency and the sickle cell community. Overall, Agios appears well-positioned for future growth and product launches.Read More>---
AGIO Stock 12 Month Forecast
Average Price Target
$62.33
▲(81.24% Upside)
Technical Analysis
Best Analysts Covering AGIO
1 Year
1 Year Success Rate
14/24 ratings generated profit
1 Year Average Return
+18.79%
reiterated a buy rating 27 days ago
Copying Gregory Renza's trades and holding each position for 1 Year would result in 58.33% of your transactions generating a profit, with an average return of +18.79% per trade.
---